Actively Recruiting
Circadian Mechanisms, Glucose, and CV Risks in T1D
Led by University of Illinois at Chicago · Updated on 2025-08-11
100
Participants Needed
1
Research Sites
233 weeks
Total Duration
On this page
Sponsors
U
University of Illinois at Chicago
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
People with type 1 diabetes are disproportionately affected by cardiovascular disease (CVD). Short and irregular sleep have been associated with cardiovascular risk in this population. Improving sleep regularity has been associated with improved glycemic markers however mechanisms by which improving sleep regularity improves metabolic and cardiovascular health is not known. The investigators propose to conduct a mechanistic study using a sleep stability manipulation. This proposal will advance the understanding of mechanisms by which improving sleep regularity influences glycemic control and cardiovascular risk in T1D.
CONDITIONS
Official Title
Circadian Mechanisms, Glucose, and CV Risks in T1D
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18-50 years with a clinical diagnosis of type 1 diabetes for at least one year
- Report habitual sleep irregularity of 1 hour or more per week
- Desire to improve sleep
- Own a smartphone (Android or iPhone)
You will not qualify if you...
- Self-reported A1C of 10% or higher within the past 6 months
- Insomnia symptoms with Insomnia Severity Index score of 15 or higher
- History of restless leg syndrome
- History of severe hypoglycemia in the past 6 months requiring emergency care
- Working rotating shifts, night shifts, or routinely sleeping after 3 AM
- Use of sleep medications or aids
- Significant medical conditions such as heart failure, cirrhosis, COPD requiring oxygen, active cancer treatment, or dialysis
- Depression with Patient Health Questionnaire 8 score of 15 or higher
- History of stroke with neurological deficits
- Pregnant, breastfeeding, or planning pregnancy
- Allergy to lidocaine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Illinois Chicago
Chicago, Illinois, United States, 60612
Actively Recruiting
Research Team
P
Pamela Martyn-Nemeth, PhD
CONTACT
S
Sirimon Reutrakul, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here